Evigrade
DrugsCosmetic ingredientsCalculatorsInteractionsEvigrade SkinEvigrade Meds ↗
ConditionsJournalMethodologyPro for practitioners
ESRU

Guaifenesin

AEMPS

Expectorant

ATC code: R05CA03

Brand names: Mucinex, Robitussin

Updated · Methodology

Indications

C

Productive cough

Adjunct

Guaifenesin is an over-the-counter expectorant. The AEMPS Frispec label words the indication carefully: the product helps reduce phlegm and bronchial secretions in productive forms of cough in adults and children over 2. The Cochrane review of over-the-counter medicines for acute cough (2014) found mixed results for guaifenesin: in some trials expectoration came easier, in others there was no difference from placebo. So this is a supportive measure rather than treatment: fluids and humidified air help, and the illness still resolves on its own schedule. The label forbids two things: using the product for chronic or persistent cough, asthmatic cough included, and combining it with cough suppressants – one thins the sputum, the other blocks bringing it up. A cough lasting beyond three weeks is investigated rather than syruped.

Sources

  1. AEMPS: Ficha técnica Frispec 6,5 mg/ml jarabe (2026)
  2. Cochrane: Over-the-counter (OTC) medications for acute cough in children and adults in community settings (2014)

ICD-10: R05 · ICD-11: MD12

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

D

Common cold

Not recommended

Guaifenesin sits in cold powders and syrups alongside paracetamol, phenylephrine and dextromethorphan. These kits sell as an all-symptoms-at-once remedy, yet each component treats its own symptom and rarely are all of them needed together. The 2014 Cochrane review of over-the-counter medicines for acute cough found no convincing evidence of benefit for expectorants or for combinations. The practical problem with combinations lies elsewhere: a cough suppressant often stands next to guaifenesin, and the AEMPS label calls that pairing illogical outright, because it blocks expectoration. The second risk is the paracetamol inside: someone takes the sachet and a separate antipyretic, and the daily dose is exceeded without notice. In children under 2 these products are contraindicated.

Sources

  1. Cochrane: Over-the-counter (OTC) medications for acute cough in children and adults in community settings (2014)
  2. AEMPS: Ficha técnica Frispec 6,5 mg/ml jarabe (2026)

ICD-10: J00 · ICD-11: CA00

F

Fibromyalgia

Not recommended

The guaifenesin protocol for fibromyalgia has been promoted since the 1990s: the theory holds that retained phosphates cause the pain, guaifenesin flushes them out, and a temporary worsening is presented as proof the scheme works. The phosphate hypothesis was never confirmed, and guaifenesin has one indication – productive cough – written into the AEMPS label. The 2017 recommendations for fibromyalgia do not mention guaifenesin: exercise comes first, then cognitive behavioural therapy, with selected drugs for severe pain or disturbed sleep. The main cost of the protocol is not guaifenesin's adverse effects, which are modest, but the months lost: a person in real pain keeps strict salicylate restrictions in cosmetics and food instead of treatment that works. If guaifenesin has been suggested for fibromyalgia, consider seeking a second opinion from a rheumatologist.

Sources

  1. EULAR: EULAR revised recommendations for the management of fibromyalgia (2017)
  2. AEMPS: Ficha técnica Frispec 6,5 mg/ml jarabe (2026)

ICD-10: M79.7 · ICD-11: MG30.01

How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

Guaifenesin irritates the gastric mucosa, and through the vagus nerve the bronchial glands put out more watery secretion. Sputum becomes more plentiful and thinner, and the cough more productive. The measurable effect is modest: studies show changes in viscosity and expectorated volume, but barely any in how people feel or how long the illness lasts. Absorption is fast, the drug breaks down within an hour and leaves as metabolites in urine. It does not run through cytochrome P450 enzymes and hardly binds plasma proteins, so it carries no significant drug interactions – which is exactly what made guaifenesin a fixture of combination cold products. One practical detail from the label: for 24 hours after a dose, a guaifenesin metabolite distorts urinary tests for 5-hydroxyindoleacetic and vanillylmandelic acid.

Safety

Contraindications

  • Hypersensitivity to guaifenesin or to any excipient
  • Children under 2 years
  • Chronic and persistent cough, including asthmatic and smoker's cough (per the label)

Serious adverse effects

  • Hypersensitivity reactions: rash, urticaria, angioedema
  • Urinary stones with prolonged very high doses (stones formed from a guaifenesin metabolite have been described)

Common adverse effects

  • Nausea and vomiting
  • Abdominal pain
  • Diarrhoea
  • Drowsiness

Pregnancy: can you take Guaifenesin?

Data in pregnancy are insufficient, and the AEMPS Frispec label sets a condition: the product is not used during pregnancy unless the expected benefit to the mother outweighs the possible risk to fetal development. A cold cough settles by itself, so fluids, humidified air and time are the usual choice.

Breastfeeding: can you take Guaifenesin?

Whether guaifenesin passes into breast milk is unknown, and the label says so plainly. No harm to the infant has been described after a single dose in a breastfeeding woman, though prolonged use without a clear indication makes no sense.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Guaifenesin used for?

Guaifenesin is evaluated for the following indications with varying evidence strength: Productive cough (evidence tier C), Common cold (evidence tier D), Fibromyalgia (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Guaifenesin?

Common side effects of Guaifenesin (≥ 1 in 100): Nausea and vomiting, Abdominal pain, Diarrhoea, Drowsiness. See the Safety section for uncommon and serious reactions.

Is Guaifenesin safe during pregnancy?

Data in pregnancy are insufficient, and the AEMPS Frispec label sets a condition: the product is not used during pregnancy unless the expected benefit to the mother outweighs the possible risk to fetal development. A cold cough settles by itself, so fluids, humidified air and time are the usual choice.

Is Guaifenesin compatible with breastfeeding?

Whether guaifenesin passes into breast milk is unknown, and the label says so plainly. No harm to the infant has been described after a single dose in a breastfeeding woman, though prolonged use without a clear indication makes no sense.

Who should not take Guaifenesin?

Guaifenesin is contraindicated in: Hypersensitivity to guaifenesin or to any excipient; Children under 2 years; Chronic and persistent cough, including asthmatic and smoker's cough (per the label). Full list in the Safety section.

Official sources

Direct links to regulator labels. Open in a new tab.

Other drugs in this group

Acetylcysteine, Ambroxol, Bromhexine, Carbocisteine, Cloperastine, Dextromethorphan, Ivy leaf dry extract (Hedera helix), Paracetamol + Chlorpheniramine + Phenylephrine